Baricitinib: therapeutic potential for moderate to severe atopic dermatitis

References

• Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.
   PubMed Web of Science ®Google Scholar
• Silverberg NB. Typical and atypical clinical appearance of atopic dermatitis. Clin Dermatol. 2017;35(4):354–359.
   PubMed Web of Science ®Google Scholar
• Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, and treatment. Immunol Allergy Clin North Am. 2015;35(1):161–183.
   PubMed Web of Science ®Google Scholar
• Torres T, Ferreira EO, Gonçalo M, et al. Update on atopic dermatitis. Acta Med Port. 2019;32(9):606–613.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, He H, Krueger JG, et al. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1–11.
   PubMed Web of Science ®Google Scholar
• Ungar B, Garcet S, Gonzalez J, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603–613.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Wang AR, Li WQ, et al. The burden of atopic dermatitis: summary of a report for the national eczema association. J Invest Dermatol. 2017;137(1):26–30.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65–S76.
   PubMed Web of Science ®Google Scholar
• Moyle M, Cevikbas F, Harden JL, et al. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756–768.
   PubMed Web of Science ®Google Scholar
• Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review. J Am Acad Dermatol. 2017;76(4):745–753.e19.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36.
   PubMed Web of Science ®Google Scholar
• He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–192.
   PubMed Web of Science ®Google Scholar
• Bao L, Shi VY, Chan LS. IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro: relevant in the pathogenesis of atopic dermatitis. Cytokine. 2013;61:419–425.
   PubMed Web of Science ®Google Scholar
• Stritesky GL, Muthukrishnan R, Sehra S, et al. The transcription factor STAT3 is required for T helper 2 cell development. Immunity. 2011;28;34(1):39–49.
   Web of Science ®Google Scholar
• Szilveszter KP, Németh T, Mócsai A. Tyrosine kinases in autoimmune and inflammatory skin diseases. Front Immunol. 2019;9(10):1862.
   Google Scholar
• Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120:150–155.
   PubMed Web of Science ®Google Scholar
• Bao L, Shi VY, Chan LS. IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: implication for atopic dermatitis. Mol Immunol. 2012;50:91–97.
   PubMed Web of Science ®Google Scholar
• Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136:667–677.
   PubMed Web of Science ®Google Scholar
• Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171:217–28.e13.
   PubMed Web of Science ®Google Scholar
• Rochman Y, Kashyap M, Robinson GW, et al. Thymic stro- mal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. Proc Natl Acad Sci USA. 2010;107:19455–19460.
   PubMed Web of Science ®Google Scholar
• Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out?. Clin Rev Allerg Immunol. 2016;51:263–292.
   PubMed Web of Science ®Google Scholar
• Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11(5):467–474.
   PubMed Web of Science ®Google Scholar
• Renert-Yuval Y, Guttman-Yassky E. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. Ann Allergy Asthma Immunol. 2020;124(1):28–35.
   PubMed Web of Science ®Google Scholar
• Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142:1121–1130 e1127.
   PubMed Web of Science ®Google Scholar
• Mihara R, Kabashima K, Furue M, et al. Nemolizumab in moderate to severe atopic dermatitis: an exploratory analysis of work productivity and activity impairment in a randomized phase II study. J Dermatol. 2019;46:662–671.
   PubMed Web of Science ®Google Scholar
• Nygaard U, Vestergaard C, Deleuran M. Emerging treatment options in atopic dermatitis: systemic therapies. Dermatology. 2017;233(5):344–357.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102–2110.
   PubMed Web of Science ®Google Scholar
• Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol. 2017;26(1):28–35.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of 187 fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe 188 atopic dermatitis inadequately controlled by conventional treatments: A 189 randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018;78:872–881.e6.
   Web of Science ®Google Scholar
• Simpson EL, Imafuku S, Poulin Y, et al. A phase 2 randomized trial of 244 apremilast in patients with atopic dermatitis. J Invest Dermatol. 2019;139:1063–245 1072.
   PubMed Web of Science ®Google Scholar
• Werfel T, Layton G, Yeadon M, et al. Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:1830–1837 e1834.
   PubMed Web of Science ®Google Scholar
• Damsky W, BA K. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744.
   PubMed Web of Science ®Google Scholar
• Serra López-Matencio JM, Morell Baladrón A, Castañeda S. JAK-STAT inhibitors for the treatment of immunomediated diseases. Med Clin (Barc). 2019;3;152(9):353–360.
   Web of Science ®Google Scholar
• He H, Guttman-Yassky E. Correction to: JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):193.
   PubMed Web of Science ®Google Scholar
• Muller R. JAK inhibitors in 2019, synthetic review in 10 points. Eur J Intern Med. 2019;66:9–17.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16:843–862.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company, Incyte Corporation. European Commission approves once-daily olumiant tablets for treatment of adults with moderate-to-severe active rheumatoid arthritis [media release]. 13 Feb 2017.
   Google Scholar
• Baricitinib CID=44205240. PubChem database: national center for biotechnology information
   Google Scholar
• Napolitano M, Fabbrocini G, Cinelli E, et al. Profile of baricitinib and its potential in the treatment of moderate to severe atopic dermatitis: a short review on the emerging clinical evidence. J Asthma Allergy. 2020;13:89–94.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT01870388, A pharmacokinetic study of baricitinib in participants with liver disease; 2017 [cited 2020 Apr 22] Available from: https://clinicaltrials.gov/ct2/show/results/NCT01870388?term=baricitinib&phase=0&draw=2&rank=4
   Google Scholar
• Shi JG, Chen X, Lee F, et al., The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 54(12): 1354–1361. 2014.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Silverberg JI, Nemoto O, et al., Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 80(4): 913–921. 2019.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Lacour J-P, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020.
   Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in moderate to severe atopic dermatitis: results of a phase 3 randomized, double-blind, placebo-controlled 16-week trial (BREEZE-AD7). Madrid, Spain: European Academy of Dermatology and Venereology (EADV); 2019 Oct 9–13.
   Google Scholar
• Mogul A, Corsi K, McAuliffe L. Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother. 2019;53(9):947–953.
   PubMed Web of Science ®Google Scholar
• Markham A. Baricitinib: first global approval. Drugs. 2017 Apr;77(6):697–704.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Baricitinib (Olumiant): summary of product characteristics; [2017; cited 2019 Dec 31] Available from: http://ec.europa.eu/health/documents/communityregister/2017/20170213136870/anx_136870_en.pdf
   Google Scholar
• Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–1252.
   PubMed Web of Science ®Google Scholar
• Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88–95.
   PubMed Web of Science ®Google Scholar
• Konrad RJ, Higgs RE, Rodgers GH, et al. Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a sensitive and specific novel immunoassay. Sci Rep. 2019;9(1):5211.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298–5307.
   PubMed Web of Science ®Google Scholar